G

Gary S. Firestein

La Jolla Institute for Immunology

ORCID: 0000-0003-3495-960X

Publishes on Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Monoclonal and Polyclonal Antibodies Research. 453 papers and 47.9k citations.

453Publications
47.9kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

NF-κB: a key role in inflammatory diseases
Paul P. Tak, Gary S. Firestein|Journal of Clinical Investigation|2001
Cited by 3.9kOpen Access

Activation of the NF-B/Rel transcription family, by nuclear translocation of cytoplasmic complexes, plays a central role in inflammation through its ability to induce transcription of proinflammatory genes (1). This pathway is activated upon appropriate cellular stimulation, most often by signals related to pathogens or stress. Here we will discuss the specificity of various NF-B proteins, their role in inflammatory disease, the regulation of NF-B activity by IB proteins and IB kinase (IKK), and the development of therapeutic strategies aimed at inhibition of NF-B.

Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Beatrix Bartók, Gary S. Firestein|Immunological Reviews|2009
Cited by 1.9kOpen Access

Rheumatoid arthritis (RA) remains a significant unmet medical need despite significant therapeutic advances. The pathogenesis of RA is complex and includes many cell types, including T cells, B cells, and macrophages. Fibroblast-like synoviocytes (FLS) in the synovial intimal lining also play a key role by producing cytokines that perpetuate inflammation and proteases that contribute to cartilage destruction. Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage. Recent advances in understanding the biology of FLS, including their regulation regulate innate immune responses and activation of intracellular signaling mechanisms that control their behavior, provide novel insights into disease mechanisms. New agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.